Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease
SPARC Health, a collaborative effort between Park City Angels (PCA), BioUtah, BioHive, in partnership with Governor’s Office of Economic Opportunity (GOEO), announced applications are now open for its second cohort program.
Taking place on March 12, 2026, at the Hilton Salt Lake City Center, the competition provides early-stage healthcare companies with a premier platform to showcase innovations to experienced investors and industry leaders.
Check out the photo gallery from the 2026 JP Morgan Healthcare conference in San Francisco.
The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular procedures.
State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease
Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform.
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing
As we look back at 2025, we’re thankful for the progress our team and partners helped drive this year.